GLP-1 Drugs May Cut Death Risk in Type 1 Diabetes

What Was Studied — and Why It Matters

GLP-1 receptor agonists — the class of drugs that includes well-known medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — are FDA-approved for Type 2 diabetes and weight loss. But doctors have increasingly been prescribing them "off-label" for people with Type 1 diabetes as well. Researchers wanted to know: is this practice actually helping patients stay healthier and alive?

This study, published in Diabetes Technology & Therapeutics in 2026, looked at over 8,400 Type 1 diabetes patients over a two-year period to find out.

What the Researchers Found

Using a large medical database, researchers compared two matched groups of Type 1 diabetes patients — those taking a GLP-1 medication and those who were not. The results were striking:

• 82% lower risk of death in the group using GLP-1 medications
• 70% fewer hospitalizations compared to the non-GLP-1 group
• 44% fewer emergency room visits
• 48% fewer endoscopy procedures (scopes used to examine the digestive tract)
• Significantly fewer prescriptions for laxatives and gut-motility drugs, suggesting better digestive health overall

Importantly, the GLP-1 group did not experience higher rates of diabetic ketoacidosis (DKA) or dangerous low blood sugar (hypoglycemia) — two serious concerns doctors often have when using these medications in Type 1 patients.

What This Means in Plain English

Simply put: Type 1 diabetes patients in this study who took GLP-1 medications ended up much less likely to die or end up in the hospital compared to similar patients who didn't take them. That's a meaningful finding, especially since these drugs are not yet officially approved for Type 1 diabetes.

It's worth noting this was an observational study — meaning researchers looked back at existing patient records rather than running a controlled experiment. That means we can't say with 100% certainty that the GLP-1 drugs caused these better outcomes, but the numbers are hard to ignore.

What Patients and Caregivers Should Know

If you or a loved one has Type 1 diabetes, this research is worth discussing with your endocrinologist or diabetes care team. GLP-1 medications are not a replacement for insulin — people with Type 1 diabetes will always need insulin — but these drugs may offer meaningful added benefits.

Managing Type 1 diabetes still requires consistent monitoring, careful insulin dosing, and reliable supplies. MDS Diabetes offers a wide range of diabetes management supplies — from CGM sensors to insulin pump accessories — to help patients stay on top of their daily care no matter what medications are part of their regimen.

Bottom Line

A large real-world study found that Type 1 diabetes patients using GLP-1 medications had dramatically lower death rates and far fewer hospitalizations and ER visits over two years — without increased risk of DKA or dangerous low blood sugar. While more research is needed before these drugs are officially approved for Type 1 diabetes, the findings are promising and worth a conversation with your care team.